SI-BONE, Inc. (SIBN) Form 10-Q — Nov 3, 2026
SI-BONE reported Q3 2026 revenue of $55.7 million, up 14.5% year over year, driven by 19.5% procedure volume growth and expanded adoption among interventional spine physicians in ASC and OBL settings. Net loss narrowed to $3.6 million from $4.6 million a year ago, and the company generated $4.4 million of positive operating cash flow over the first nine months. The company holds $146.3 million in cash and marketable securities against $36.0 million of term loan debt, and management said existing resources fund operations for at least the next 12 months. A Fifth Amendment with First-Citizens Bank in September 2026 revised financial covenant testing periods.
Key figures
- Revenue
- 55704000
- Total Debt
- 36000000
- Revenue Yoy
- 14.5%
- Cash Position
- 146300000
- Shares Outstanding
- 45113087
- Gross margin q3
- 79.3%
- Q3 2025 revenue
- 48656000
- Nine month revenue
- 164302000
- Nine month revenue yoy
- 13.6%
- Implants voluntarily recalled
- 98
- Operating cash flow nine month
- 4355000
- Implants repackaged resterilized
- 3900
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.